v3.26.3
License Agreements - Narrative (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 177 Months Ended
Feb. 28, 2026
USD ($)
shares
Feb. 23, 2026
USD ($)
shares
Feb. 10, 2025
USD ($)
renewal_option
Jan. 07, 2025
shares
Jan. 07, 2024
USD ($)
shares
Jul. 28, 2023
USD ($)
Feb. 28, 2026
USD ($)
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
Jan. 31, 2012
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Other research and development               $ 43,740 $ 35,543 $ 174,528 $ 106,038    
Total revenue               259,936 161,709 705,189 423,713    
License                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total revenue               19,893 $ 2,392 28,044 $ 5,898    
LFB License Agreement                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Other research and development                       $ 31,000  
Accounts payable               0   0   0  
License agreement, term                         15 years
Royalty expense               25,100   70,100      
Accrued royalties               25,100   25,100   25,100  
Commercialization Agreement with Neuraxpharm                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Collaboration agreement, one-time, non-refundable payment           $ 140,000              
Milestone payment, upon commercial launch           12,500              
Additional milestone payment, upon achievements of commercial launch           $ 482,500              
Royalty percentage on net product sales           0.30              
Deferred revenue               33,200   33,200   33,200  
Unconditional right to receive payments               $ 12,100   12,100   $ 12,100  
Percentage of all costs reimbursed up to opt in date               0.25          
Percentage of eligible costs reimbursed up to opt in date               0.25          
Commercialization Agreement with Neuraxpharm | Royalty                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total revenue               $ 4,100   $ 10,400      
Commercialization Agreement with Neuraxpharm | License                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total revenue               10,000          
Net product sales               50,000          
Commercialization Agreement with Neuraxpharm | Other                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total revenue               $ 5,000          
Precision License Agreement | Precision BioSciences, Inc.                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
License agreement, trading days             30 days            
Precision License Agreement | Precision BioSciences, Inc.                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
License agreement, term 10 years           10 years            
Additional milestone payment, upon achievements of commercial launch $ 286,000           $ 286,000            
License agreement, amount paid upfront   $ 7,500     $ 7,500   7,500            
License agreement, amount paid upfront, cash 5,250 5,250     5,250   5,250            
License agreement, amount paid upfront, equity investment $ 2,250 $ 2,250     $ 2,250   $ 2,250            
Investment owned, balance (in shares) | shares 201,504 201,504   220,712 2,920,816                
Deferred payment         $ 2,500                
License agreement, percentage of premium on equity investment         1                
License agreement, trading days   30 days   30 days 30 days                
License agreement, payment, percentage of weighted average share price 2 2   2     2            
Strategic Platform License Agreement                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
License agreement, term     10 years                    
Additional milestone payment, upon achievements of commercial launch     $ 13,000                    
License agreement, amount paid upfront     1,000                    
Annual license fee     $ 200                    
Number of milestone events to have the option to extend term | renewal_option     1                    
License agreement term extension     5 years                    
Written notice period     90 days